CNR2 and Parkinson disease: Considering that it has been shown that GW842166x was safe and well-tolerated in a clinical trial, the results from this study suggest that the use of GW842166x or of other CB2 agonists could be a potential therapeutic strategy to slow disease progression in the early phase of PD [69,70].